Influence of anticancer drugs on DNA methylation in liver of female mice

Shaden Muawia Hanafy¹, Tarek Abd El-Raouf Salem¹, Amal Ahmed Abd El-Aziz¹, Bahgat Abd El-Ghafar El Fiky², Mahmoud Abd El-Azeim Shokair¹

¹Molecular Biology Department, Genetic Engineering and Biotechnology Institute, Minufia University, Shibin El Kom, Egypt; ²Animal Biotechnology Department, Genetic Engineering and Biotechnology Institute, Minufia University, Shibin El Kom, Egypt. E-mail: shadenmuawia@yahoo.com

Received 18 March 2011; revised 16 May 2011; accepted 29 May 2011.

ABSTRACT

Epigenetic changes such as DNA methylation regulate gene expression in normal development. Methotrexate and Adriamycine are antineoplastic drugs that target DNA and enzymes acting on DNA. We aimed to evaluate their cytotoxic effect on cell lines and on female mice to investigate the in vivo influence of both drugs on the DNA methylation and subsequently the protein expression. The total level of DNA methylation showed a significant reduction from 62.2% to 36.7%, 36.6% as compared to control group, when using different doses of MTX and ADR. Hepatic protein pattern revealed five bands with low MW (16 - 6.1 KDa) in acute and LD50 doses. In conclusion DNA methylation is influenced by anticancer drugs in a dose-dependent manner. Some specific protein fragments may be considered as a potential markers associated with high dose of anticancer drugs.

Keywords: Epigenetic; DNA Methylation; Methotrexate (MTX); Adriamycine (ADR)

1. INTRODUCTION

Cancer is uncontrolled growth of cells coupled with malignant behavior; invasion and metastasis. It is thought to be caused by the interaction between genetic susceptibility and environmental toxins. Most of chemotherapeutic drugs work by impairing mitosis and/or inducing apoptosis. Several anticancer drugs target DNA or enzyme acting on the DNA [1]. The resistance of tumor cells to different antineoplastic agent is an obstacle for cancer chemotherapy. The main mechanism in drug resistance is the multi-drug resistance (MDR) phenomenon, which constitutes the reduction of intracellular drug level due to the P-glycoprotein pump function [2]. Drug development programs for identification of new cancer chemotherapeutic agents involve extensive preclinical evaluation of vast numbers of chemicals for detection of antineoplastic activity. Animal models have always played an important role, and also cell culture systems have figured largely in the field of cancer chemotherapy, where the potential value of such systems for cytotoxicity and viability testing is now widely accepted [3].

Methotrexate (MTX)—is an antimetabolite and antifolate drug which is used in treatment for many neoplastic disorders and some autoimmune diseases. It inhibits the synthesis of nucleic acids and subsequently proteins [4]. However, MTX, at certain dose, exhibited a toxic side effect to normal cells and organs in the body. Also, using of MTX for long period can increase the risk of toxicity [5]. Many studies proved the ability of MTX to inhibit dihydrofolate reductase enzyme (DHFR) which converts dihydrofolate to the active tetrahydrofolate compound which is essential for DNA methylation. [6].

Adriamycin (ADR) is an anthracycline isolated from streptomyxin peucetius. It is commonly used in the treatment of a wide range of cancer including haematological malignancies, carcinomas, sarcomas and lymphomas. It prevents DNA replication by acting as topoisomerase inhibitor [7].

DNA methylation is a major biochemical modification, typically occurs at 5'-CpG (Cytosine-phosphate-guanine sites). They are regions have a higher GC content than the genome average and they may repress transcription [8]. In mammals, almost 60% of all promoters localize within CpG region. These regions are commonly devoid of methylation, while the rest have a methylation pattern and base composition indistinguishable from bulk DNA [9]. There is an inverse relationship between CpG methylation and transcriptional activity. Evidence that has
accumulated in the past 10 years suggests that cancer cells usurp this physiologic mechanism and use it to their benefit by inactivating tumor suppressor genes leading to cancer progression. Hypomethylating agents or DNA methylation inhibitors could be used for the reversal of aberrant DNA methylation and therefore restore the function of silenced genes in cancer causing growth arrest in tumor cells [10,11]. Upon these observations, we designed this work to investigate the potential activity of two common anticancer drugs, MTX and ADR as DNA hypomethylating agents that may lead to hyper expression of some genes associated with tumor suppression.

2. MATERIALS AND METHODES

2.1. Cell Lines and Cytotoxic Drugs

Three different types of cell lines were used for in vitro study; human larynx carcinoma cell line (Hep2, ATCC No. CCL-23), human hepatocyte carcinoma cell line (HepG2, ATCC No. HB-8065) and monkey kidney cell line (Vero, ECACC No. 84113001). Cell lines were maintained and grown in RPMI culture medium supplemented with 15% fetal bovine serum (FBS), 10 mmol/L HEPES, 1 mmol/L sodium pyruvate, 4.5 g/L glucose, 1.5 g/L sodium bicarbonate, and 5% penicillín/streptomycin (Reagents and chemicals were obtained from Sigma/Aldrich, USA). Two different chemotherapeutic drugs were used, methotrexate (10 mg/1ml; Ebewe Co. Italy) and adriamycin (2 mg/1ml; Pharmacia Co. Italy). Drugs were diluted in 0.9% physiological saline for 1X concentration.

2.2. In-Vitro Cytotoxic Study

Cells were seeded in 96-well flat-bottomed microtiter plates (100 µl/well) under complete aseptic condition and incubated in 5% CO₂ incubator at 37°C for 24 hr to reach complete monolayer. Serial dilutions of tested drugs were titrated in triplicate to the cells; in addition to the control wells that left without drugs. The plate was then incubated in 5% CO₂ incubator at 37°C for 24 hr and 72 hr to investigate the LD50 and cytotoxic effect of the tested drugs. For recovery period bioassay, plates were incubated for 7 days in which growth medium was renewed every 2 days.

2.3. In-Vivo Cytotoxic Study

The toxicity study was carried out using 70 female Balb/c mice weighing 20 - 25 g each. They were maintained on animal cubes (Feeds Nigeria Ltd), provided with water ad libitum and were allowed to acclimatize to the laboratory conditions for seven days before the experiment. Three doses were selected for each drug according to LD50 determinaion on cell lines: For adria-
Figure 1. Percentage of cytopathic effects 24 hr after incubation with drugs and recovery percentage after 72 hr from drugs elimination.

\[ \cdots 5'\text{C} \downarrow \text{CGG} \cdots 3' \]
\[ \cdots 3'\text{GG C} \uparrow \text{C} \cdots 5' \]

MspI and HpaII differ in sensitivity to DNA methylation. MspI cleaves outer and inner methylated cytosines (mCCGG or CmCGG). While Hpa II cleaves outer cytosines in this DNA sequence (mCCGG). On this base, we could determine the percentage of methylated fragments of genomic DNA. The samples of DNA were analyzed by using 1% agarose gel in TAE buffer containing ethidium bromide (at final concentration of 1 mg/ml) [20]. 1kb DNA (ladder 250 - 10000 bp-Promega, USA) was used as standard DNA. The electrophoresis was performed at 100 mA for 3 hours. Individual fragments of DNA were detected by UV-trans-illuminator and photographed. For densitometrical scanning of DNA preparations and data evaluation, we used the Gel documentation system, the software Microsoft Photo Editor, Ingenius Syncene Bioimaging, Canada, software version 5.

2.8. Statistical Analysis

Statistical analysis was done using the statistical package SPSS version 10. Comparison of mean values of studied variables among different groups was done using ANOVA test. \( p < 0.05 \) was considered to be significant.

3. RESULTS

3.1. In-Vitro Cytotoxicity Study on Hep2, HepG2 and Vero Cell Lines

He percentage of cytopathic effect of MTX and ADR were calculated and presented in Figure 1. Results showed that MTX exhibited higher cytopathic effect against HepG2, Hep2 and Vero cell lines as compared to that of ADR after 24 hr exposure. Furthermore, HepG2 cells were more susceptible to the toxicity of MTX and ADR as it exhibited a significant percentage of growth.

Figure 2. Biochemical parameters among different injected groups with ADR compared to control.

Figure 3. Biochemical parameters among different injected groups with MTX compared to control.

Figure 4. A photomicrograph of normal liver of female mice (a) and injected with therapeutic MTX (b) showing dilated central vein congested with blood cells, fatty changes and vacuolar degeneration of hepatocytes.
inhibition (79.1% and 71.5%, respectively); while the percentage of recovered cells after 72 hr were 23.6% and 25.7%, respectively. In contrast, the Hep2 and Vero cell lines exposure time 24 hr were more resistant to the cytotoxic effect of both MTX and ADR (54.6% and 43.1% for Hep2, 58.2% and 41.6% for Vero cell line); while the recovery cells after 72 hr proved the differential cytotoxicity for MTX and ADR.

3.2. Biochemical and Hematological Investigations

Treatment of ADR group of mice with different doses, revealed a significant difference between the sub groups when compared with control. The difference was very highly significant in case of AST, blood urea, serum creatinine and haemoglobin. (p = 0.001) as shown in Figure 2. While, in case of MTX group. The difference was very highly significant between the subgroups compared to control in AST, ALT, blood urea and haemoglobin (p = 0.000) as shown in Figure 3.

3.3. Histopathology

Liver, kidney and spleen biopsies of female mice injected with therapeutic doses of MTX and ADR for one month showed some histopathological changes when compared to normal control group as shown in Figures 4, 5, 6(a) and (b)). While, in case of toxic doses, it showed marked histopathological changes especially in kidney.

3.4. Protein analysis

Figure 7 illustrates the pattern of hepatic protein elec-
trophoresis of the studied groups of animals. Regarding the band with MW 130 KDa was presented in normal and therapeutic ADR dose. The band which had MW 136 KDa was presented in normal only and disappeared in all groups. The bands which had MW 134.06, 130.44, 120.30, 100.31 and 97.45 KDa were presented in normal and therapeutic ADR and therapeutic MTX. These bands were not observed in animals injected with acute and LD50 doses of ADR or MTX. This band can be considered as a potential marker associated with therapeutic dose of anticancer drugs. They showed appearance of two bands (18.1 and 16.7 KDa) in animals treated with acute, LD50 and therapeutic doses of ADR and MTX, while not shown in control groups. Five bands had been shown with low molecular weight (range size 16 - 6.1 KDa) in animals exposed to acute and LD50 doses of ADR and MTX. These bands were not observed in the controls, and in animals injected with therapeutic dose of ADR and MTX. These bands can be considered as a potential marker associated with high dose of anticancer drugs.

3.5. DNA Methylation Study

Representative electrophoreograms of hepatocyte DNA of control and injected groups digested with Msp I or HpaII were demonstrated in Figures 8 and 9. The electrophoreograms were scanned densitometrically. The scans were divided into molecular weight intervals calculated from the migration of the standard DNA. On densitometrical scans, curves of non-digested DNA and DNA treated by the restriction enzymes had different shapes. The shape of curves was influenced also by the MTX and ADR (Figures 9, 11(a) and (b)). On the basis of densitometrical scans, molecular weight distribution of products of DNA cleavage with restriction enzymes Msp I and Hpa II was calculated. The results of analyses of DNA fragments obtained by treatment with the restriction enzymes Msp I and Hpa II, summarized in Table 1.

It showed that the total level of DNA methylation was influenced not only by anticancer drugs but also by their doses. Treatments related alterations liver DNA methylation in the typical methylation sequence C-C-G-G were expressed as a total methylation percentage in different MTX and ADR subgroups. Total methylation percentage was markedly reduced from 62.2% (control) to 36.7% by the action of the hypomethylating agents MTX and ADR.
**Table 1.** Percentage of hepatic DNA methylation among different groups of the study.

<table>
<thead>
<tr>
<th>Sample</th>
<th>N</th>
<th>MW (Kb)</th>
<th>Mn (Kb)</th>
<th>R</th>
<th>% Methylation</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Msp I</td>
<td>12</td>
<td>2.5</td>
<td>0.86</td>
<td>2.90</td>
<td>62.2</td>
<td>0.001124</td>
</tr>
<tr>
<td>Hpa II</td>
<td>12</td>
<td>3.0</td>
<td>0.53</td>
<td>5.66</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Therapeutic MTX</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Msp I</td>
<td>12</td>
<td>3.1</td>
<td>0.67</td>
<td>4.62</td>
<td>36.7</td>
<td>0.079478</td>
</tr>
<tr>
<td>Hpa II</td>
<td>12</td>
<td>2.9</td>
<td>0.49</td>
<td>5.91</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute MTX</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Msp I</td>
<td>12</td>
<td>1.75</td>
<td>0.69</td>
<td>2.53</td>
<td>38.0</td>
<td>0.001124</td>
</tr>
<tr>
<td>Hpa II</td>
<td>12</td>
<td>3.21</td>
<td>0.50</td>
<td>6.42</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LD50 MTX</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Msp I</td>
<td>12</td>
<td>3.01</td>
<td>0.78</td>
<td>3.85</td>
<td>39.3</td>
<td>0.001124</td>
</tr>
<tr>
<td>Hpa II</td>
<td>12</td>
<td>2.89</td>
<td>0.56</td>
<td>5.16</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Therapeutic ADR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Msp I</td>
<td>12</td>
<td>3.7</td>
<td>0.97</td>
<td>3.81</td>
<td>36.6</td>
<td>0.003341</td>
</tr>
<tr>
<td>Hpa II</td>
<td>12</td>
<td>3.25</td>
<td>0.71</td>
<td>4.57</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute ADR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Msp I</td>
<td>12</td>
<td>2.25</td>
<td>0.74</td>
<td>3.04</td>
<td>37.0</td>
<td>0.079478</td>
</tr>
<tr>
<td>Hpa II</td>
<td>12</td>
<td>3.01</td>
<td>0.54</td>
<td>5.57</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LD50 ADR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Msp I</td>
<td>12</td>
<td>3.32</td>
<td>0.81</td>
<td>4.09</td>
<td>36.9</td>
<td>0.003341</td>
</tr>
<tr>
<td>Hpa II</td>
<td>12</td>
<td>2.99</td>
<td>0.58</td>
<td>5.15</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The mass average MW = \( \sum Xi \times Mi \), where Wi is the mass fraction and Mi the average weight for interval i. Individual intervals were obtained from gel photographs, which were scanned; scans were divided into MW intervals calculated from the migration of standard DNA molecules. The number average MW = \( \sum Xi \times Mi \), where Xi is number fraction for interval i. For the number average distribution, the relative number of molecules under each interval was summed and the number in each interval of molecules was taken as a fraction of the total DNA. R is the ratio (MW/Mn), a change in the value of r indicated a change in the shape of the distribution. Percentage of methylation = 1 – (Mn Msp I)/(Mn HpaII) × 100.

The reduction was in a dose-dependent manner. There was a highly significant reduction in MTX therapeutic, LD50 and ADR therapeutic as well as LD50 in comparison to control group (p = 0.0011, 0.0033, respectively). Significant difference was found especially in products of cleavage with enzyme MspI, where a decrease in DNA fragments of medium molecular weight (1 - 7 kb) occurred between the therapeutic MTX dose and therapeutic ADR dose than control. MTX and ADR of acute and LD50 did not induce significant changes in molecular weight distribution of restriction fragments of DNA isolated from acute and LD50 treatment with MTX or ADR.

**4. DISCUSSION**

Epigenetic changes such as DNA methylation act to regulate gene expression in normal mammals. In the present study, the higher level of DNA methylation observed in control than treated female mice was probably connected with alterations in the gene expression of the hepatocytes. It was obviously recognized in the SDS-PAGE for total soluble hepatic protein patterns. As it showed absence or presence of some protein bands after treatment with anti-cancer drugs comparing to untreated group. This finding is in agreement with the report of David [21] and this observation relies on the type of drug used and in a dose-dependent manner. Five bands had been shown with low molecular weight (16 - 6.1 KDa) after treatment with acute or LD50 dose of ADR, and meanwhile with acute and LD50 dose of MTX. These bands were not observed either in the control or therapeutic ADR or therapeutic MTX. These bands can be considered as a potential marker associated with high dose of anticancer drugs. The changes in band intensity or density could be explained on the basis of cytogenetical abnormalities produced by these drugs. Donna et al., [22] concluded that the increase in band intensities or densities could be due to the gene duplication produced by induction of bridges, breaks, laggards, and micronuclei. The disappearance of some bands could be attributed to the loss of some genetic material. It seems possible that interaction of diet and contaminants or drugs by inducing changes in DNA methylation and aberrant gene expression. Specific methylation alterations are associated with changes in gene expression and this association is described by the simple hypothesis that methylation turns some genes off and others on. Our data and data from several studies indicated that DNA methylation changes are much complicated and its pattern is generally discontinuous. This can be observed by comparing Msp I partial digested DNA with comparable Hpa II digests. Since differential methylation clearly exists in DNA, it is likely that gene expression has evolved to utilize these differences (up and down of regulation different genes) [23]. This was strongly supported by our data and reflected by different protein banding pattern for the different treated groups of animal comparing to control. Inhibition of DNA methylation (hypomethylation) as a result of anti cancer drugs or post-radiation therapy had been reported by Igor, et al. [24]. Hypomethylation showed the loss of long interspersed nucleotide element-1 (LINE-1) CpG methylation in spleen.

Recent study of Basak, et al. [25] reported that the cytotoxic effect of MTX is associated with apoptosis enhancement, as it may be related to hyperhomocysteinemia and deoxyribonucleotide pool imbalances. Concluding that there was an altered expression of MTHFR enhanced MTX—induced myelosuppression in mice, after evaluating that in the major hemolytic organ spleen. DNA methylation-related anticancer drugs had gained increasing attention over the past decades due to the aberrant DNA methylation to development of drug resistant tumors cells. Hence the acquired drug resistance represents a frequent obstacle which hampers efficient chemotherapy of cancers [26]. Recently, Boettcher et al. [27] characterized DNA methylation change which arises...
es from treatment of tumor cells with the adriamycine. DNA methylation level from CpG islands linked to twenty eight genes whose expression levels had been shown to contribute with the resistance against DNA double strand break induced drugs. These data were supported in some way to our data in documenting DNA methylation by different doses of doxorubicin drug in non-tumor female mice [28] assessed the CpG methylation aberrations induced by pixantrone and doxorubicin. A characteristic that may determine the most cancer types to specific drug treatments and is a marker of drug sensitivity. Moreover, Winter-Vann, et al. [29] suggested that MTX has an additional mechanism of action besides it is a potent product inhibitor of cellular methyltransferases. It is also having an inhibitory effect on Ras signaling that regulates cell growth and differentiation. Because carboxyl methylation of Ras is important for proper plasma membrane localization and function, they reported that after MTX treatment of DKO88 cells, Ras methylation is decreased by almost 90% and subsequently inhibition of carboxyl methylation.

5. CONCLUSIONS

DNA methylation is influenced by anticancer drugs (MTX and ADR) and this influence was in a dose-dependent manner; as they exhibited reduction in DNA methylation with varying degrees in liver genomic DNA. Some specific protein bands may be considered as a potential markers associated with high doses of anticancer drugs. Treatment with DNA methylation inhibitors may reactivate epigenetically silenced genes and has been shown to restore normal gene function. Further studies are recommended to characterize the protein fragments associated with anticancer drugs treatment.

REFERENCES


